Articles

McKesson to acquire Celesio AG for approximately $8.3 billion

McKesson will acquire majority stake in the company for approximately $31 per share
| 3 min read

SAN FRANCISCO—McKesson Corporation and Celesio AG have announced the signing of an agreement by which McKesson will acquire a majority stake in Celesio for 23 euros (approximately $31.78) per share and launch parallel voluntary public tender offers for Celesio’s remaining publicly traded shares and outstanding convertible bonds. The offer price represents a 39-percent premium over the three-month volume weighted average price prior to Oct. 8, when market speculation of a transaction began. All told, the total transaction, which includes the assumption of Celesio’s outstanding debt, has an approximate value of 6.1 billion euros (approximately $8.3 billion).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.